eH1N1_f

eH1N1_f is an egg-derived, inactivated monovalent subunit influenza vaccine developed by Novartis Vaccines (now part of CSL Seqirus) to address the 2009 H1N1 influenza pandemic (swine flu). The vaccine is composed of purified surface antigens, primarily hemagglutinin (HA) and neuraminidase, derived from the A/California/07/2009 (H1N1)v-like virus strain. In clinical development, eH1N1_f was evaluated as a standalone unadjuvanted formulation and in combination with the MF59 oil-in-water adjuvant (the latter often referred to as Focetria). The vaccine works by stimulating the production of strain-specific neutralizing antibodies that target the viral hemagglutinin protein, thereby preventing the virus from binding to and entering host respiratory cells. It was studied in Phase 3 trials to assess safety and immunogenicity across various age groups, including children, adolescents, and adults.

Other names

Novartis egg-derived H1N1 influenza vaccineA/H1N1 S-OIV Monovalent Subunit Influenza Virus VaccineA/H1N1 S-OIV vaccineegg-derived inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine